Medication info

Pregabalin Capsule 75 mg (Pregabalin)

Prescription medicationApproval withdrawn
Ingredient · strength
Pregabalin›Strength being verified
Manufacturer / importer
Korea United Pharm Co., Ltd.
Appearance
A hard capsule with a brown-red upper part and a white lower part containing white powder that is white or light yellow.
Packaging
Domestic: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle Export: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle, 60 capsules (10 capsules/PTPX6)
Approval status
Approval withdrawn

MFDS item code 201109145 · Approved 2011.10.25

This product's status changed to Approval withdrawn on 2023.05.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually withdrawn over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration schedule | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Additional dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The additional dose refers to a supplemental dose administered once. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with decreased renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Korea United Pharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for patients with epilepsy who experience partial seizures, aiding in seizure control. Furthermore, it is effective in alleviating pain associated with fibromyalgia. It is used to improve a variety of neuropathic pain and abnormal symptoms.

Dosage and Administration

Adult dosage

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually withdrawn over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration schedule | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Additional dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The additional dose refers to a supplemental dose administered once. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with decreased renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or mood changes occur during treatment, consult a doctor immediately. Do not take if you are allergic to any of the ingredients in this medication, and patients with specific genetic lactose metabolism disorders should avoid it as well. Diabetic patients may experience weight gain after taking this medication, which may require dosage adjustment of blood sugar control medications. If symptoms of angioedema, such as swelling around the face or neck, occur, stop taking the medication immediately and inform a healthcare professional. Elderly patients should be cautious as this medication may cause dizziness or drowsiness, increasing the risk of accidents such as falls. This medication may cause temporary blurred vision or changes in vision; if these symptoms occur, consult a doctor. Withdrawal symptoms, such as headaches, anxiety, and insomnia, may occur if the medication is discontinued abruptly, so gradual tapering is recommended, under the supervision of a healthcare professional. This medication has a risk of abuse, so patients should disclose their mental health status and medication history accurately to their healthcare provider. Patients with decreased kidney function may require dosage adjustments. Patients with severe heart disease should use caution when taking this medication. When taken with other CNS depressants, the risk of drowsiness or respiratory depression may increase, so caution is advised. Early pregnancy poses a risk of fetal malformations; therefore, pregnant women or those planning to become pregnant should consult a doctor, and fertile women should use effective contraception. Breastfeeding may transfer this medication into breast milk and affect the baby, so consult a healthcare provider regarding breastfeeding. This medication can cause dizziness and drowsiness, so it is advisable to avoid driving or operating dangerous machinery after taking it. In cases of overdose, severe drowsiness, confusion, depression, etc., may occur; seek medical attention immediately.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 178 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • melancholy
  • pain
  • excessive sweating
  • dizziness
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical muscle spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorder
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling of intoxication
  • paresthesia
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • directional disorientation
  • irritability
  • resilience
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood fluctuations
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • speech disturbance
  • sensory disturbances
  • sensory reduction
  • sedation
  • excessive drowsiness
  • cognitive impairment
  • nystagmus
  • language impairment
  • myoclonus
  • reduced reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesis
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • respiratory distress
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • pruritus
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • lability
  • restlessness
  • seizures
  • worsening of convulsions
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture exposure. It is important to maintain storage temperature between 15 to 30 degrees Celsius to preserve the efficacy and safety of the medication.

Appearance and packaging

Appearance

A hard capsule with a brown-red upper part and a white lower part containing white powder that is white or light yellow.

Package unit

Domestic: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle Export: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle, 60 capsules (10 capsules/PTPX6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.